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Objective. Inﬂammatory cytokines released by hypertrophic adipocytes contribute to low-grade inﬂamma-
tion, a characteristic of Type 2 Diabetes. Skeletalmuscle contraction during physical activity stimulates the secre-
tion of anti-inﬂammatory cytokines able to counteract this inﬂammatory status. The aim of this study was to
review the evidence of the effectiveness of walking as a physical activity intervention to reduce inﬂammation.
The interplay between adipose tissue and skeletal muscle contributions was also investigated.
Method. A structured literature review of papers available up to December 2014 was carried out within the
PubMed, Scopus and ISI Web of Science databases using the keywords “walking” and “inﬂammation” in order
to identify the studies involving healthy subjects and subjects diagnosed with, or at increased risk of, Type 2
Diabetes.
Results. Thirty-two studieswere reviewed,ﬁve investigating the acute effects ofwalking and twenty-seven its
chronic effects (n= 21 interventional and n=6 observational). Acute effects of walking bouts led to an increase
of interleukin-6 in one study, althoughwithout any increase in the concentration of the anti-inﬂammatorymark-
er interleukin-1 receptor antagonist. Eight interventional studies showed a signiﬁcant reduction of inﬂammation.
A reduction in tumour necrosis factor-α concentration was often associated with an adiposity reduction. The
observational studies showed that individuals who walk more present a lower inﬂammatory status.
Conclusion. There is no consensus regarding the efﬁcacy of walking in the reduction of low-grade systemic
inﬂammation, even though a relationship cannot be excluded. In each walking bout, no anti-inﬂammatory effect
due to the IL-6-stimulated myokine cascade can be demonstrated.© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Recent evidence suggests that the metabolic dysfunctions at the
origin of Type 2 Diabetes (T2D) are associated with changes in the
immune system, which include altered plasma levels of speciﬁc
pro-inﬂammatory proteins and cytokines, a phenomenon known as
“systemic low grade inﬂammation” (Duncan et al., 2003; Hotamisligil,
2006; Kolb and Mandrup-Poulsen, 2005; Schmidt et al., 1999). For this
reason T2D has been classiﬁed as an inﬂammatory disease (Donath
and Shoelson, 2011; Pradhan et al., 2001).
This inﬂammatory process originates in the adipose tissue as a con-
sequence of chronic positive energy balance (excess calorie intake and/
or low physical activity), which leads to adipocyte hypertrophy and
macrophage inﬁltration (Kershaw and Flier, 2004). This scenario fa-
vours the release of “unhealthy” adipokines – the cytokines secreted
by the adipose tissue – including, among others tumour necrosis factor
alpha (TNF-α) and interleukin 6 (IL-6),which regulate the release of the
acute phase reactant C-reactive protein (CRP) from the liver (Wellen
and Hotamisligil, 2005; Zhang et al., 2006). The activation of the
described inﬂammatory pathway appears to be linked to the onset of in-
sulin resistance (Yudkin et al., 1999) in the peripheral tissues, namely
the skeletal muscle and adipose tissue, which is an early factor of the
pathogenesis of T2D (DeFronzo and Tripathy, 2009). Thus, reducing
the mass of the adipose tissue seems to be the way to counteract this
inﬂammatory status. Lifestyle modiﬁcations, such as diet and physical
activity, are the elective modality to reach this goal (Arvidsson et al.,
2004; Bastard et al., 2000; Bruun et al., 2006).
The recent ﬁndings that allow the skeletal muscle to be considered
as an endocrine organ (Pedersen and Febbraio, 2012) have questioned
the role played by IL-6 within the previously described inﬂammatory
cascade (Febbraio et al., 2004). This stimulated new research
concerning the widely recognized association between T2D, obesity
and low physical activity. In fact, IL-6 has been identiﬁed as the ﬁrst
“myokine”, i.e. as the ﬁrst cytokine secreted by skeletal muscle contrac-
tion (Steensberg et al., 2000), which induces a cascade of anti-
inﬂammatory cytokines (Interleukin-10: IL-10 and Interleukin-1 recep-
tor antagonist IL-1ra) (Petersen and Pedersen, 2005; Mathur and
Pedersen, 2008). Thus, IL-6 seems to have a ubiquitous role (Fisman
and Tenenbaum, 2010) and the relationship between its inﬂammatory
adipokine and anti-inﬂammatory myokine nature has not yet been
completely elucidated. This apparent paradox is possibly explained by
the transient secretion of myokines, and notably IL-6, during skeletal
muscle activity, whichmight represent one of themechanisms blocking
the inﬂammatory signalling pathways generated by chronically elevat-
ed levels of pro-inﬂammatory adipokines (Handschin and Spiegelman,
2008; Lambernd et al., 2012; Starkie et al., 2003). The inactive skeletal
muscle becomes an additional source of pro-inﬂammatory cytokines
(IL-6 and TNF-α) with respect to the adipose tissue, which contributes
to enhancing the systemic inﬂammatory status (Handschin and
Spiegelman, 2008). Considering that during contraction a skeletal mus-
cle secretes cytokines with anti-inﬂammatory properties (e.g. IL-10 and
IL1-ra), physical activity can potentially act through two different cate-
gories of mechanisms to control the inﬂammatory status: the ﬁrst one
entails the direct control of the source of inﬂammation (mainly reduc-
ing the adipose tissue mass), whereas the second one occurs during
each physical activity bout through the indirect stimulation of the secre-
tion of anti-inﬂammatory cytokines (Gleeson et al., 2011) from the
skeletal muscle.Walking is a suitable physical activitymodality to preventmany risk
factors for T2D (Murtagh et al., 2015; Qiu et al., 2014). In addition, an
intervention aimed at increasing or maintaining the level of walking
activity is normally easy to implement and is applicable to different
populations, including obese and elderly individuals and, more broadly,
people with low ﬁtness levels, who, conversely, could encounter difﬁ-
culties in performing more vigorous activities (Morris and Hardman,
1997).Whereas the effect of other types of physical activity on markers
of low-grade systemic inﬂammation has been extensively reviewed
(Hayashino et al., 2014; Hopps et al., 2011; Nimmo et al., 2013;
Petersen and Pedersen, 2005), we are not aware of previous studies to
date that have systematically reviewed the effect that walking can
have on inﬂammation.
Thus, the aim of this review is to systematize the existing knowledge
about the relationship betweenwalking activity at any intensity and key
markers of chronic low-grade inﬂammation, focusing on the implica-
tions for T2D.More speciﬁcally, the review aims to answer the following
questions: 1) could walking be an appropriate physical activity for the
reduction of low-grade systemic inﬂammation? 2) Can the potential
beneﬁcial effects of walking on the reduction of chronic low-grade
inﬂammation originate from sources other than adipose tissue mass
reduction? 3) If this is the case, can the potential beneﬁcial effects be
mediated by contracting skeletal muscles?
Methods
Eligibility criteria
This review targeted English-language studies dealing with:
- Adult subjects (≥18 years) belonging to the following categories:
a) healthy, b) having impaired glucose tolerance or metabolic
syndrome and c) diagnosed with T2D;
- Walking activity and inﬂammatorymarkers, as observed in random-
ized clinical trials, experimental, or cross-sectional studies. In partic-
ular, CRP, IL-6, and TNF-α were investigated as primary markers of
low-grade inﬂammation, having extensively been reported to be
the primary proteins and cytokines involved in the inﬂammatory
process (Pickup, 2004; Shoelson et al., 2006).
Exclusion criteria
Studies regarding animals, including diet as lifestyle modiﬁcation, or
combining walking with other types of physical activity have been
excluded from the analysis.
Search strategy
Articles published up to December 2014 were identiﬁed by
searching on PubMed, Scopus and ISI Web of Science and by cross-
reference check. The keywords used in the search are outlined in
Supplementary Table 1.
Screening
The screening process of articles by title, abstract and full article was
performed based on the eligibility criteria. Fig. 1 displays the screening
process of the articles.
Fig. 1. Systematic review procedure ﬂowchart.
540 M. Morettini et al. / Preventive Medicine Reports 2 (2015) 538–547Data extraction
Extracted information included year of publication, studydesign, ob-
jective, participant characteristics (sex, age, bodymass index (BMI), and
health status), sample size, outcome measurements, and assessment
methodology.
Results
As a result of the above search, thirty-two articles were identiﬁed.
Five of them investigated the acute response (Davis et al., 2008;
Markovitch et al., 2008; Murtagh et al., 2005; Nelson and Horowitz,
2014; Nieman et al., 2005) to a walking bout and the remaining
twenty-seven focused on the chronic effects of walking activity. As de-
tailed in Table 1, twenty-one out of the twenty-seven studies regarding
chronic effectswere interventional (eleven randomized controlled trials
and ten non-randomized trials) and six observational (ﬁve including a
cross-sectional comparisons of subjects classiﬁed by activity levels and
one being a cohort study).
Acute response to walking bouts
One of the ﬁve studies dealing with the acute effects of walking
(Markovitch et al., 2008) involved twelve sedentary male volunteers
(age 54 ± 4 years; BMI 28.0 ± 3.0 kg/m2) who underwent a single
walking bout of moderate intensity (30 min at 50% of maximal oxygenuptake (V˙O2max), estimated intensity of 5.2 ± 0.7 METs (METs, multi-
ple of energy consumption at rest)). IL-6, IL-10, and CRP concentrations
did not change at 0, 2, 24, 48, 72, and 168 h following the trial. Similarly,
no signiﬁcant differences were found in plasma CRP when twelve sed-
entary healthy post-menopausal women (age 58 ± 6 years; BMI
25.6 ± 3.4 kg/m2) completed two 30-minute treadmill brisk walking
exercises (50% and 70% of their maximal heart rate (HRmax), correspond-
ing to 35% and 60% estimated V˙O2max, respectively), (Davis et al., 2008),
or inﬁfteenobesemale subjects (age 50±6years; BMI 30.9±4.9 kg/m2)
after a 45-minute walking at 60% V˙O2max (Murtagh et al., 2005).
A slight but signiﬁcant increase in serum IL-6 concentration, not as-
sociated with changes in IL-1ra concentration, was observed 1 h after a
30-minute intervention consisting of treadmill walking at 60–65% V˙O2
max in ﬁfteen women (age 37 ± 3 years; non-obese) who were accus-
tomed to regular walking (Nieman et al., 2005). In a later trial (Nelson
and Horowitz, 2014), IL-6 and TNF-α concentrations remained un-
changed one day after a session of exercise (1 h of treadmill brisk walk-
ing at 70% of HRmax) performed by twenty-four healthy subjects, twelve
(male/female: 5/7; age 27 ± 2 years; BMI 30.9 ± 1.0 kg/m2) of which
were “regular-exercisers” and twelve (male/female: 5/7; age 28 ±
2 years; BMI 30.1 ± 0.5 kg/m2) “non-exercisers”.
It has to be highlighted that the study by Nelson and Horowitz
(2014) has been included among those on the acute effects for the
purpose of this review despite the fact that IL-6 was measured one
day after the walking bout. From the other studies, however, it might
be deduced that walking bouts do not seem to activate the IL-6 based
Table 1
Chronic effect studies: study design, method, details and outcomes.
Author/year Study design Type Method Data analysis Outcome related to inﬂammation
Balducci et al.
(2010)
Randomized clinical trial. 20 out of 82
subjects (9 F and 11 M aged 63 ± 7 years;
BMI 30.0 ± 1.0 kg/m2) with T2D or
metabolic syndrome performed physical
activity of low intensity (walking) for 12
months
Interventional Diaries Blood concentrations
of CRP, TNF-α and
IL-6
↘ CRP: 12% reduction from baseline
observed at 12 months (not signiﬁcant)
↔ BMI, waist circumference and fat mass
observed at 3, 6, 9, 12 months from
baseline
Dekker et al.
(2007)
24 middle-aged men (8 lean, 8 obese, and
8 obese with T2D) performed 60 min of
walking or jogging 5 times per week
(about 60% V˙02max) for 12 weeks
without a reduction in body weight
Interventional Treadmill Blood concentrations
of TNF-α, IL-6 and
CRP
↓ IL-6 concentration in all groups (52%,
32%
and 17% reduction in the T2D, lean and
obese groups, respectively)
↔ CRP levels
↓ Total and visceral adiposity in all groups
Di Raimondo
et al. (2013)
176 patients affected by metabolic
syndrome (95 M and 81 F, mean age 59 ±
7 years; BMI 31.6 ± 4.8 kg/m2)
completed a 24-week walking
intervention (1 h/day, 5 days/week) at a
walking velocity higher than the
comfortable one
Interventional Pedometers Blood concentration
of CRP before and
after the intervention
↓ BMI
↓Waist circumference
↓ CRP
Dixon et al.
(2013)
9 active lean (age 52 ± 1 years; BMI 23.8
± 0.7 kg/m2; waist circumference
b84 cm) and 9 active central overweight
men (age 49 ± 1 years; BMI 29.3 ± 1.2;
waist circumference
N94 cm) reduced their walking activity to
less than 4000 steps/day for one week
Interventional Pedometers Blood concentration
of TNF-α, IL-6 and
CRP before and after
the intervention
↔ TNF-α
↔ IL-6
↔ CRP
Gano et al.
(2011)
11 middle-aged/older adults (5 M and 6 F,
age 57–70 years; BMI 26.2 ± 1.0 kg/m2)
completed a 2-month brisk walking
intervention (6 days/week, 50 min/day) at
70% HRmax
Interventional Diaries + HR
monitors
Blood concentrations
of TNF-α, IL-6 and
CRP before and after
the intervention
↔ TNF-α
↔ IL-6
↔ CRP
↓ BMI
↓ Total body fat
Giannopoulou
et al. (2005)
Randomized, controlled trial, 33 women
(age, 50–70 years) were assigned to
diet alone (D), exercise alone (EX), or
diet + exercise (D + E) for 14 weeks. The
EX intervention consisted of a supervised
walking programme 3 to 4 times per
week for 60 min at 65% to 70% V˙02max
Interventional Supervised
exercise
Blood concentrations
of TNF-α, IL-6 and
CRP
↓ CRP decreased in all groups after the
interventions, but no differences between
groups
↘ Trend for IL-6 concentrations to
decrease
(P= 0.07) in all groups, with no
differences between groups
↔ TNF-α
↔ BMI and total body fat in the EX group
Gray et al.
(2009)
Randomized controlled trial. Control
group
(6 M, 18 F; age 51 ± 8 years; BMI 29.5 ±
5.9 kg/m2), intervention group (5 M, 19 F;
age 48 ± 9 years; BMI 27.6 ± 4.9 kg/m2).
12 weeks pedometer-based walking
program. Intervention is designed to
increase mean daily step count by 3000
steps/day on at least 5 days of the week
program
Interventional Pedometers Blood concentrations
at baseline and after
12 weeks of TNF-α,
CRP, IL-6
↔ TNF-α, CRP, IL-6
↔ BMI, body fat percentage
Hamer and
Steptoe
(2008)
Cross sectional analysis including 185
healthy participants (107 M, 78 F) aged
45–59 years
Observational Questionnaires
and weekly
minutes of
walking
Blood concentrations
of TNF-α and IL-6
↓ Time spent walking inversely related to
TNF-α
↘ Trend observed for IL-6 to decrease
Ho et al.
(2013)
Randomized controlled trial. 16 subjects
(age range 40–66; BMI range 26–48)
assigned to control group and 15 subjects
(age range 44–62; BMI range 25–46)
assigned to 12-week walking training at
moderate intensity
(30 min at 60% V˙02max, 5 days/week)
Interventional Treadmill Blood concentration
of TNF-α and IL-6
↓ TNF-α in overweight and obese
individuals compared to no exercise
↔ IL-6
Izzicupo et al.
(2013)
Non randomized trial. 32
post-menopausal women (age 56 ± 4
years; BMI 26.9 ± 4.3 kg/m2) performed
13 weeks of walking training at moderate
intensity (40–50 min,
4 days/week)
Interventional Activity
monitors +
diaries
Plasma
concentrations of
TNF-α and CRP
↓ TNF-α
↔ CRP
↔BMI, waist circumference and fat mass
percentage
Jennersjö et al.
(2012)
Observational cross-sectional analysis
including 327 individuals with T2D (224
M, 103 F; age 54–66 years). Individuals
wore the pedometer for 3 days.
Classiﬁcation of physical activity in 4
groups
Observational Pedometers and
diaries
Blood concentrations
of CRP and IL-6
Steps/day signiﬁcantly associated with
lower levels of CRP and IL-6. When
adjusted for waist circumference, the
association between steps and IL-6
remains statistically signiﬁcant but the
association between steps and CRP does
(continued on next page)
541M. Morettini et al. / Preventive Medicine Reports 2 (2015) 538–547
Table 1 (continued)
Author/year Study design Type Method Data analysis Outcome related to inﬂammation
not
Klenk et al.
(2013)
Population-based cohort study.
Community-dwelling individuals aged
over 65 underwent a baseline assessment.
710 M and 543 F (mean age 76 ± 7 years)
Observational Accelerometer
(1 week) to
determine
average duration
of daily walking
Blood concentration
of CRP at baseline
↔ For CRP quartiles 1 and 2, no signiﬁcant
difference was present followed by a dose
response association
Krause et al.
(2014)
Randomized controlled trial. Twenty-ﬁve
sedentary, obese (BMI N 30 kg/m2) males
(53 ± 7 years); 12 controls versus 13 T2D
subjects were randomly allocated to four
groups that exercised for 16 weeks.
Exercise consisted in 30 min/day, three
times per week either at low (30–40%
V˙02max) or moderate (55–65% V˙02max)
intensity
Interventional HR monitors Blood concentrations
of CRP, TNF-α and
IL-6 at baseline and
after 16 weeks of
intervention
↔ CRP, TNF-α, IL-6
Krogh-Madsen
et al. (2010)
Clinical trial. Ten healthy human males
(mean age 24 ± 2 years; BMI 22.1 ±
0.7 kg/m2). None of the participants
walked less than 3500 steps/day.
Decrease the number of daily steps to
1500 for 14 days
Interventional Pedometer Blood concentrations
of TNF-α and IL-6 at
baseline and after 2
weeks
↔ TNF-α, IL-6
↓ Total body mass reduced
Lund et al.
(2011)
Randomized controlled trial. 10 sedentary
men (age 57 ± 2 years, BMI 27.9 ± 3.6
kg/m2) undertook 30min of daily walking
at 60% V˙02max for 1 week versus control
(normal sedentary behaviour)
Interventional Supervised
exercise
Blood concentrations
of TNF-α, IL-6 and
CRP
↔ TNF-α, IL-6 and CRP
Marcell et al.
(2005)
Randomized controlled trial. Fifty-one
subjects (20 M and 31 F; BMI 33.7 ±
4.8 kg/m2) aged 45 ± 8 years were
selected. No history of diabetes.
Participants were randomized to 3 groups
(control, moderate exercise and intense
exercise) for 16 weeks of intervention.
Moderate exercise was based on complete
30 min of physical activity most days of the
week. All subjects were inactive at baseline.
17 subjects performed moderate exercise
Interventional Daily diaries and
supervised
exercise
Blood concentration
of CRP
↔ CRP
Improvements in body composition
McNeilly et al.
(2012)
Eleven participants (6 M and 5 F; age
49 ± 9 years; BMI 32.4 ± 7.1 kg/m2) with
impaired glucose tolerance, completed a
12-week brisk walking intervention (30
min/day, ﬁve days/week at 65% of HRmax)
Interventional HR monitors +
diaries
Blood concentration
of CRP
↔ CRP
↔ Dietary intake
↓ BMI and total body fat
Neuparth et al.
(2014)
Cross-sectional study. 30 patients with
T2D who walked regularly during the last
year (17 M and 13 F; age 62 ± 11 years;
BMI 26.6 ± 4.4 kg/m2) and 53 patients
with T2Dwho did not perform any type of
exercise (25 M and 28 F; age 63 ± 10
years; BMI 28.1 ± 3.6 kg/m2)
Observational Questionnaires Blood concentration
of CRP
↓ CRP levels decreased in active T2D
patients with respect to inactive T2D
patients, but signiﬁcance lost after
adjustment for BMI
Nishida et al.
(2014)
Cross-sectional study. 737 middle-aged
male subjects (age 57 ± 8 years; BMI 23.9
± 2.9 kg/m2) and 1838 middle-aged
female subjects (age 56 ± 8 years; BMI
22.6 ± 3.1 kg/m2) were monitored for 10
days to determine their physical activity
level
Observational Accelerometers Blood concentrations
of TNF-α and IL-6
↓ Number of steps was inversely
associated with TNF-α even after
adjusting for BMI↔ IL-6
Puglisi et al.
(2008)
Randomized controlled trial. 12 out of 34
subjects (6 M and 6 F; age 55 ± 4 years,
BMI 27.9 ± 3.9 kg/m2) assigned to a walk
group for 6 week
Interventional Pedometers Blood concentration
of TNF-α.
↑ Daily steps for 6 week from 6000 to
11,000 steps/day
↔ TNF-α
↔ Body mass and waist circumference
Riesco et al.
(2013)
16 late pre-menopausal women (49 ± 3
years; BMI 31.9 ± 3.0 kg/m2) and 14 early
postmenopausal (53 ± 2 years; BMI 30.8
± 1.9 kg/m2) overweight and obese
involved in 16-week walking programme
(three sessions of 45 min/week at 60% of
heart rate reserve). Brisk walking
Interventional Supervised
exercise
Blood concentrations
of TNF-α and IL-6
↑ TNF-α in both groups
↔ IL-6
↓ BMI, waist circumference and fat mass
signiﬁcantly reduced after adjustment for
age
Smith et al.
(2009)
Randomized controlled trial involving
41 sedentary adults (8 M, 33 F). 2 groups:
1) 16 weeks of internet delivered physical
activity intervention (age 40 ± 2 years;
BMI 31.4 ± 1.1 kg/m2); 2) usual care
(age 47 ± 1 years; BMI 31.0 ± 0.7 kg/m2)
Interventional Pedometer and
questionnaires
Blood concentration
of TNF-α and CRP
↑ Increased mean number of steps/day by
1404 in intervention group
↔ CRP
↓ TNF-α in the intervention group after
adjustment for baseline group differences
↓Waist circumference in the intervention
group after controlling for age and baseline
differences
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Table 1 (continued)
Author/year Study design Type Method Data analysis Outcome related to inﬂammation
Taghian et al.
(2012)
Randomized controlled trial involving 20
elderly women. 10 were assigned to
control group (age 68 ± 4 years; BMI 31.3
± 4.4 kg/m2) and 10 to intervention
group (age 69 ± 3; BMI 28.0 ± 3.7
kg/m2). 12-week walking intervention
consisting in three walking session per
week for three months
Interventional Treadmill Blood concentration
of IL-6, TNF-α and
CRP
↓ BMI, TNF-α and CRP
↔ IL-6
Yakeu et al.
(2010)
17 healthy sedentary individuals (9 M
and 8 F of mean age 46 ± 11 years, mean
BMI 26.8 ± 5.1 kg/m2) undertook an
8-week low-intensity exercise
programme (walking 10,000 steps/day,
three times/week).
Interventional Supervised
exercise
Plasma concentration
of IL-6 and IL-10
↓ IL-6 decreased 33% within 4 weeks
↑ IL-10
↔ BMI
Yates et al.
(2008)
Cross-sectional study including 400
participants normal, with pre-diabetes,
with diabetes (mean age 62 ± 9 years)
Observational Questionnaires Blood concentrations
of IL-6, TNF-α and
CRP
↓ IL-6, CRP and TNF-α level in group
reporting walking for at least 30 min on at
least 5 days/week compared group
reporting lower walking activity, after
adjustment for potential confounders.
Further adjustment for waist
circumference attenuated the association
of walking with TNFα, although the
association with IL-6 and CRP remained
signiﬁcant.
Yates et al.
(2010)
Randomized controlled trial including
74 participants (age 65 ± 8 years) with
impaired glucose tolerance and BMI
over 25.
3 groups: 1) pedometer; 2) without
pedometer; 3) usual care. 12 months
Interventional Pedometer and
questionnaire
Blood concentrations
of IL-6 and CRP at
baseline and after 12
months
↔ IL-6 and CRP
Ambulatory activity was signiﬁcantly and
inversely associated with IL-6 after
adjustment for potential confounders
(age, ethnicity, sex, group, medication
status,
baseline and change in BMI)
Zoppini et al. 16 sedentary (8 M and 8 F), overweight
(BMI 29.0 ± 3.0 kg/m2), non-smoking,
older patients (age 66 ± 6 years) with
T2D volunteered to participate in a
6-month, supervised, progressive, aerobic
training study, two times per week
Interventional Supervised
exercise
Plasma levels of CRP
and TNF-α at baseline
and after 6 months
↔ CRP and TNF-α
↔ BMI, waist circumference and body
weight
Abbreviations: M: male; F: female; T2D: Type 2 Diabetes; CRP: C-Reactive Protein; TNF-α: Tumour Necrosis Factor α; IL-6: Interleukin 6; V˙02max: Maximal Oxygen Uptake; BMI: Body
Mass Index.
Symbols: ↑ Signiﬁcant increase;↗ Trend to increase (not signiﬁcant);↔ No variation;↘ Trend to decrease (not signiﬁcant); ↓ Signiﬁcant decrease.
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Indeed, a non-signiﬁcant reduction of IL-6 concentration with respect
to the pre-exercise level has been reported by Murtagh et al. (2005).
Nieman et al. (2005) reported an increase in IL-6, but no increment
in plasma concentration of the anti-inﬂammatory marker IL-1ra. As
expected, no investigation of TNF-α was found among the reviewed
studies. TNF-α, in fact, is mainly secreted by the adipose tissue and
does not seemrelated to the cytokine cascade triggered by skeletalmus-
cle contraction.None of the reviewed studies reported acute variation in
the level of CRP in association to a walking intervention.
Chronic effects of walking activity
Themethods generally adopted for the assessment of physical activ-
ity performed in free-living conditions, that is, non-supervised by an
expert, can be summarized as self-reported (e.g. questionnaires and
diaries) or objective measures based on wearable sensors (e.g. acceler-
ometers, pedometers, heart rate monitors).
Out of the twenty-seven reviewed studies regarding the chronic ef-
fect of walking, eighteen dealt with free-living conditions (see Table 1).
Four of those used self-reporting assessment tools (Balducci et al., 2010;
Hamer and Steptoe, 2008; Neuparth et al., 2014; Yates et al., 2008), and
eight used objective measures (ﬁve used pedometers (Di Raimondo
et al., 2013; Dixon et al., 2013; Gray et al., 2009; Krogh-Madsen et al.,
2010; Puglisi et al., 2008), two used accelerometers (Klenk et al.,
2013; Nishida et al., 2014) and one used heart rate monitors (Krause
et al., 2014)). The remaining six studies used a combination ofself-reporting and objective assessment (Gano et al., 2011; Izzicupo
et al., 2013; Jennersjö et al., 2012; McNeilly et al., 2012; Smith et al.,
2009; Yates et al., 2010). The use of objective measurement methods
is preferred over the use of self-reporting methods because, as widely
recognized, the latter are affected by reporting biases (Prince et al.,
2008), whichmay undermine the accurate classiﬁcation and quantiﬁca-
tion of physical activity.Interventional studies
Reviewed studies using walking as physical activity intervention
modality have produced conﬂicting results. Only eight out of twenty-
one reported a signiﬁcant reduction of chronic low-grade inﬂammation
marker concentration (Dekker et al., 2007; Di Raimondo et al., 2013;
Giannopoulou et al., 2005; Ho et al., 2013; Izzicupo et al., 2013; Smith
et al., 2009; Taghian et al., 2012; Yakeu et al., 2010).
In ten sedentary overweight men (age 57 ± 2 years; BMI 27.9 ±
3.6 kg/m2), one week of 30-minute daily walking at 60% V˙O2max did
not elicit any signiﬁcant change in TNF-α, IL-6 or CRP with respect to
the baseline values (Lund et al., 2011). In addition, no signiﬁcant differ-
enceswere found in TNF-α, IL-6 or CRP plasma concentrations in eleven
subjects (age 57–70 years, BMI 26.2 ± 1.0 kg/m2) tested before and
after a two-month brisk walking intervention (6 days/week, 50 min/
day at 70% HRmax equivalent to 60% V˙O2max) (Gano et al., 2011) or in
twenty-ﬁve subjects (twelve obese controls vs. thirteen obese with
T2D, age 53 ± 7 years) that exercised for sixteen weeks (30 min/day,
three times per week either at low, 30–40% V˙O2max , or moderate,
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body composition (BMI and total body fat) was highlighted only by
Gano et al. (2011). No difference in CRP concentration was observed
in eleven obese subjects (age 49 ± 9 years; BMI 32.4 ± 7.1 kg/m2)
performing a twelve-week intervention consisting of 30 min/day of
brisk walking, 5 days/week at 65% HRmax (~50–60% V˙O2max)
(McNeilly et al., 2012), despite the same intervention being sufﬁcient
to lower BMI and total body fat, without changes in dietary intake.
Oneweek of reduced physical activity (steps/day b4000) induced no
changes in IL-6, CRP and TNF-α in nine healthy active lean (age 52 ±
1 years; BMI 23.8 ± 0.7 kg/m2; waist circumference b84 cm) and nine
healthy active central overweight men (age 49 ± 1 years; BMI 29.3 ±
1.2 kg/m2; waist circumference N94 cm) (Dixon et al., 2013). A reduc-
tion of walking from 10,000 steps/day to 1500 steps/day for fourteen
days did not lead to differences in TNF-α and IL-6 in ten healthy males
(age 24± 2 years; BMI 22.1 ± 0.7 kg/m2), despite an attenuation in in-
sulin sensitivity (Krogh-Madsen et al., 2010). Surprisingly, the subjects
showed a reduction in total body mass.
Consistent results have been reported for a walking intervention in-
volving twenty-four healthy subjects (age 48 ± 9 years; BMI 27.6 ±
4.9 kg/m2) which aimed to gradually increase the average number of
daily steps walked by the participants (Gray et al., 2009). The subjects
were observed for one week, to set a baseline value. They were then
asked to achieve the goal of walking more than 3000 steps above that
baseline value, for at least ﬁve days within the next six weeks, and
then to maintain this increase for other six weeks. The results showed
that this twelve-week walking programme did not modify TNF-α, IL-6
and CRP levels in addition to BMI and body fat percentage when com-
pared to the control group of twenty-four healthy subject (age 51 ±
8 years; BMI 29.5 ± 5.9 kg/m2). A similar study including twelve sub-
jects (age 55±4; BMI 27.9±3.9 kg/m2) did not show anymodiﬁcation
in TNF-α concentration from the baseline after a six-week intervention,
which led to an increase in steps/day from 6000 to 11,000 (Puglisi et al.,
2008). In this study, no modiﬁcation of body mass or waist circumfer-
ence was detected.
A further walking intervention protocol prescribed 60min of walking
at 60% V˙O2max, ﬁve times per week for twelve weeks, to twenty-four
middle aged subjects (Dekker et al., 2007) who also followed a dietary
programmedesigned tomaintain bodymass. The intervention led to a re-
duction of IL-6 levels, visceral and total adiposity. This reduction was sig-
niﬁcant evenwhen the subjectswere divided into three sub-groups: lean,
obese and obese with T2D (age 48 ± 3 years, 47 ± 3 years and 51 ±
3 years, respectively). The intervention, however, did not lead to signiﬁ-
cantly altered CRP levels. A consistent reduction of IL-6 was also detected
when seventeen healthy adults (age 46 ± 11 years, BMI 26.8 ± 5.1 kg/
m2) performed an eight-week low-intensity exercise intervention
consisting of walking 10,000 steps/day (Yakeu et al., 2010). The IL-6 con-
centration decreased to approximately two-thirds of its basal levelwithin
four weeks of beginning the exercise. At the same time, the IL-10 signiﬁ-
cantly increased and no change in BMI was observed.
A signiﬁcant decrease in BMI and fat percentage, associated with a
decrease in TNF-α and CRP and no changes in IL-6, were detected in a
randomized trial including twenty elderly women. The subjects were
assigned to either a control group (age 68 ± 4 years; BMI 31.3 ±
4.4 kg/m2) or an intervention group (age 69 ± 3 years; BMI 28.0 ±
3.7 kg/m2) who underwent a twelve-week walking programme (three
walking sessions per week, the duration and intensity of which in-
creased from 20 min at 50–55% HR reserve, ~50–55% V˙O2max , to
45–60 min at 60–70% HR reserve, ~ 60–70% V˙O2max, in the last week)
(Taghian et al., 2012).
A further randomized trial (Ho et al., 2013), compared two groups of
sedentary and lightly active healthy subjects to a twelve-week inter-
vention group (control: age 40–66 years, BMI between 26.0 and
48.0 kg/m2; intervention: age 44–62 years, BMI between 25.0 and
45.6 kg/m2). The intervention consisted of 30-minute treadmill walkingat 60% of HR reserve (~60% V˙O2max) for 5 days aweek. The TNF-α levels
were decreased by 20% at week 12 compared to the baseline in the in-
tervention group. These changes in TNF-α signiﬁcantly correlated
with a change in body fat and body fat percentage. No signiﬁcant chang-
es were observed for the IL-6 within or between groups.
The ﬁnding of a 24-week walking intervention study (1 h/day,
5 days/week) involving 176 patients with metabolic syndrome (mean
age 59 ± 8 years; BMI 31.6 ± 4.8 kg/m2) (Di Raimondo et al., 2013),
for whom the mean number of steps walked per day was less than
10,000was a decrease in BMI associatedwith a decrease in CRP concen-
tration. In contrast, another sixteen-week walking programme (three
session of 45 min/week at ~60% V˙O2max) did not modify IL-6 and CRP
levels but increased plasma levels of TNF-α in sixteen late pre-
menopausal (age 49 ± 3 years; BMI 31.9 ± 3.0 kg/m2) and fourteen
early post-menopausal (age 53 ± 2 years; BMI 30.8 ± 1.9 kg/m2)
overweight or obese women (Riesco et al., 2013). In both groups, the
intervention led to statistically signiﬁcant differences in BMI, waist
circumference and fat mass, after adjustment for age. Intriguingly, a
thirteen-week intervention (four walking sessions of 40–50 min at
moderate intensity) in thirty-two post-menopausal women (mean
age 56 ± 4 years; BMI 26.9 ± 4.3 kg/m2), showed the same results in
terms of CRP, a signiﬁcant reduction of TNF-α but a non-signiﬁcant
variation of BMI and fat mass (Izzicupo et al., 2013).
A sixteen-week intervention duration was used in a further study
(Marcell et al., 2005) where ﬁfty-one inactive overweight and obese in-
dividuals with no history of diabetes were randomized in three groups.
Out of these, seventeen (age 47 ± 9 years; BMI 33.9 ± 4.9 kg/m2)
underwent a moderate walking intervention (3.5 METS of intensity per
session), which improved their body composition, with decreased body
weight, total body fat, and BMI. However, no change in CRP levels was
found following this intervention. Conversely, another programme (four-
teen weeks of sixty minutes walking at 60% V˙O2max three or four times
per week) involving eleven overweight and obese post-menopausal
womenwith T2D (age 56± 2 years; BMI 35.9± 1.9 kg/m2) led to a sig-
niﬁcant decrease in CRP levels (Giannopoulou et al., 2005). IL-6 plasma
concentration tended to decrease, but no signiﬁcant differences from
the baseline were reported. Furthermore, no signiﬁcant differences
were observed in TNF-α, BMI or total body fat either. In a randomized
trial (Smith et al., 2009) nineteen sedentary adults (age 40 ± 2 years;
BMI 31.4±1.1 kg/m2)were assigned to sixteenweeks of walking inter-
vention. An increase of 1404 steps/day caused no effect on CRP levels,
whereas TNF-α declined signiﬁcantly.When adjusting for age and base-
line differences, waist circumference decreased in the intervention
group as well.
A group of sixteen sedentary, overweight, non-smoking, older pa-
tients with T2D (age 66 ± 6 years; BMI 29.0 ± 3.0 kg/m2) participated
in a six-month, twice a week, supervised 60-minute aerobic training in-
tervention (50% and 70% of HR reserve ~50–70% V˙O2max) (Zoppini
et al., 2006). TNF-α, CRP, body weight and waist circumference did
not change after the intervention. Twenty subjects (age 63 ± 7 years;
BMI 30.0 ± 1.0 kg/m2) with either T2D or metabolic syndrome per-
formed a low intensity walking activity for twelve months, which
caused a non-signiﬁcant decrease of 12% in CRP levels (Balducci et al.,
2010). No differences from the baseline values were found in IL-6,
TNF-α and BMI. Another study (Yates et al., 2010) involving two groups
of twenty-four overweight subjects with impaired glucose tolerance
failed to show reductions on markers of chronic low grade inﬂamma-
tion after twelve months of intervention with (age 65 ± 8 years; BMI
28.7 ± 5.0 kg/m2) and without pedometer (age 64 ± 7 years; BMI
29.3±5.1 kg/m2). However, across the study sample, a change in objec-
tively measured walking activity was signiﬁcantly and inversely associ-
ated with IL-6, after adjustment for potential confounders, including
changes in BMI. Notably, a variation of ambulatory activity by about
2500 steps⁄day, equivalent to approximately 25 min of moderate-
intensity walking activity per day, was needed to induce a 0.5 pg⁄ml
decrease in IL-6 (Tudor-Locke and Bassett, 2004).
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Reviewed observational studies provided a more univocal inverse
relationship between habitual walking activity and markers of low-
grade systemic inﬂammation. A cross-sectional study (Yates et al.,
2008) including 400 participants (age 62 ± 9 years) screened for T2D
(normal, pre-diabetic and diabetic) showed that those who reported
walking activity for at least 30 min on at least 5 days/week had lower
levels of CRP, IL-6, and TNF-α compared to those who reported lower
walking activity levels. This was after adjustment for other types of
moderate to vigorous intensity physical activity, age, ethnicity, sex,
social deprivation and smoking status. Further adjustment for waist
circumference attenuated the association of walking with TNF-α. In an-
other cross-sectional study (Hamer and Steptoe, 2008) on 185 healthy
subjects aged between 45 and 59, multiple linear regression analyses
adjusted for all confounders, revealed that time spent walking
(min/week) is inversely related to TNF-α while a non-signiﬁcant
trend was observed for IL-6.
A more recent cross-sectional study (Jennersjö et al., 2012) involv-
ing 327 individuals (aged 54–66 years) with T2D aimed to classify,
by pedometer count, four different levels of physical activity
(b5000 steps/day; 5000–7499 steps/day; 7500–9999 steps/day and
N10,000 steps/day). This study showed a signiﬁcant negative correla-
tion between the number of steps/day and CRP and IL-6 levels. When
adjusting for waist circumference, the association between IL-6 and
steps⁄day remained statistically signiﬁcant, whereas the association
between high-sensitivity CRP and steps⁄day did not reach statistical
signiﬁcance. In a cross-sectional study byNishida et al. (2014) involving
1838 individuals aged 40 to 69 years, habitual physical activity was
assessed by a single axis accelerometer. Step count was inversely asso-
ciated with TNF-α even after adjusting for BMI, whereas no signiﬁcant
differences were observed in IL-6. In another cross-sectional study
(Neuparth et al., 2014) data from thirty patients (age 62 ± 11 years;
BMI 26.6 ± 4.4 kg/m2) with T2D who walked regularly (from 30 min
up to 1 h a day, 3 to 5 times per week) during the last year and ﬁfty-
three patients (age 63 ± 10 years; BMI 28.1 ± 3.6 kg/m2) with T2D
who did not perform any type of exercise were compared. Active T2D
patients showed signiﬁcantly lower BMI and CRP levels than inactive
T2D patients, even if CRP lost signiﬁcance after adjustment for BMI.
Finally, one cohort study was found, which involved 1253
community-dwelling individuals (age 76 ± 7 years) (Klenk et al.,
2013). Stratiﬁcation for CRP quartiles after adjustment for covariates,
highlighted that an increase of 10 min per day of walking duration can
elicit signiﬁcant reduction of CRP levels.
Discussion
The ﬁrst aim of this reviewwas to assess whether walking can be an
appropriate physical activity intervention to reduce low-grade systemic
inﬂammation. The investigated interventional studies provided contro-
versial results. Only eight (Dekker et al., 2007; Di Raimondo et al., 2013;
Giannopoulou et al., 2005; Ho et al., 2013; Izzicupo et al., 2013; Smith
et al., 2009; Taghian et al., 2012; Yakeu et al., 2010) out of twenty-one
reported a signiﬁcant reduction of chronic low-grade inﬂammation,
intended as the reduction of the concentration of at least one of the in-
vestigated markers, namely CRP, IL-6 and TNF-α. Although the number
of studies showing a reduction in the low-grade systemic inﬂammation
after a walking intervention is considerably lower than those reporting
no changes, the efﬁcacy ofwalking as away to reduce low-grade inﬂam-
mation cannot be excluded. The observational studies, in fact, unequiv-
ocally showed that individuals who usually walk more have lower IL-6,
TNF-α and CRP concentrations and some, comparatively large sample,
interventional and observational studies (Di Raimondo et al., 2013;
Nishida et al., 2014; Smith et al., 2009) supported the efﬁcacy ofwalking
in reducing the inﬂammatory status.
In an attempt to identify common patterns in the studies supporting
the efﬁcacy of walking, it has been observed that impaired glucosetolerance or T2D does not seem to be particularly relevant, whereas
fat mass plays a key role. Evidence in the literature also suggests that
the increased circulating IL-6 concentrations seen in patients with T2D
are strongly related to fat mass but not to insulin responsiveness, sug-
gesting that neither IL-6 nor TNFα are indicators of insulin resistance
(Carey et al., 2004). Moreover, screening for body weight, the reviewed
studies involving overweight or obese subjects that showed a reduction
in TNF-α plasma concentration after the intervention, often reported a
concomitant reduction of adiposity (Ho et al., 2013; Smith et al., 2009;
Taghian et al., 2012). This result is also in accordance with the study
by Hotamisligil et al. (1995), demonstrating that bodyweight reduction
in obese subjects is associated with a decrease in TNF-αmRNA expres-
sion in fat tissue.
The duration of the intervention represents one of the major
determinants of the efﬁcacy of a walking intervention. In fact, even
intense interventions lasting one or two weeks (Dixon et al., 2013;
Krogh-Madsen et al., 2010; Lund et al., 2011) did not cause modiﬁca-
tions of any of the observed inﬂammatory markers, despite being
potentially effective in modifying other markers of the metabolic sys-
tem status, such as peripheral insulin sensitivity (Krogh-Madsen et al.,
2010). The shortest among the reviewed intervention studies that
induced a low-grade inﬂammation variation is an eight-week interven-
tion (Yakeu et al., 2010). The critical role of intervention duration has
also been described by Hayashino et al. (2014), who performed a
meta-analysis of fourteen randomized controlled trials involving differ-
ent types of exercise (aerobic, resistance or a combination of both). This
meta-analysis highlighted that exercise was more effective in reducing
IL-6 in longer interventions, which included a larger number of sessions.
Notably, a reduction of low-grade inﬂammation has been detected only
in studies where walking activity was supervised or objectively moni-
tored (Dekker et al., 2007; Di Raimondo et al., 2013; Giannopoulou
et al., 2005; Ho et al., 2013; Izzicupo et al., 2013; Smith et al., 2009;
Taghian et al., 2012; Yakeu et al., 2010), thus indicating that a bias
could affect self-reported quantiﬁcation of physical activity and hence
the ﬁnal outcome. The intensity of walking activity can be hypothesized
as a further determinant. Most of the reviewed studies that reported a
reduction of inﬂammation are characterized by a moderate-intensity
walking activity (Dekker et al., 2007; Giannopoulou et al., 2005; Ho
et al., 2013; Izzicupo et al., 2013; Taghian et al., 2012), conﬁrming
the well-known beneﬁcial effects of brisk walking in T2D (American
Diabetes Association, 2014; Jeon et al., 2007).
From the literature analysis the efﬁcacy of walking in the reduction
of the inﬂammatory status cannot be excluded, the review therefore
aimed to further investigate the mechanisms by which this potential
effect is exerted. In this context, the authorswanted to assess if the ben-
eﬁcial effects of walking with regards to the reduction of chronic low-
grade inﬂammation originate from sources different fromadipose tissue
mass reduction and, in particular, whether the skeletal muscles play a
role in this context. A key point to test this hypothesis is to determine
if walking induces the same anti-inﬂammatory reactions induced by
vigorous exercise, possibly in a less marked fashion. Despite the fact
that IL-6 has been shown to increase up to 100 times as a function of in-
tensity and duration of skeletal muscles contractions (Pedersen and
Febbraio, 2008), only one out of the ﬁve reviewed studies regarding
the acute effect of walking (Davis et al., 2008; Markovitch et al., 2008;
Murtagh et al., 2005; Nelson and Horowitz, 2014; Nieman et al., 2005)
reported a slight increase one hour after the walking session (Nieman
et al., 2005). Surprisingly, the only population showing an increase of
IL-6 consisted of women accustomed to regular walking (Nieman
et al., 2005). As is well known, differences in initial training level deter-
mine themagnitude of exercise-induced IL-6 responses,most likely due
to differences in muscle glycogen content between trained and un-
trained skeletalmuscles (Heinrich et al., 1990; Phillips et al., 1996). Dur-
ing acute exercise, the untrained muscle is highly dependent on
glycogen substrate and acute plasma IL-6 response is lower in trained
than untrained subjects (Pedersen and Febbraio, 2008). For this reason,
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wider IL-6 response. Moreover, no increment was detected in the anti-
inﬂammatory cytokine IL1-ra by Nieman et al. (2005). Thus, at present,
no acute effect caused by an IL-6-stimulated anti-inﬂammatory cascade
can be demonstrated. However, no deﬁnitive conclusion should be
drawn, considering the limited number of available studies.
A key role in the reduction of low-grade inﬂammation could be
played by the peroxisome proliferator-activated receptor γ co-
activator 1α (PGC1-α), which is expressed in the skeletalmuscle. An in-
crease in PGC1-α expression is one of the main adaptations due to
chronic exercise. PGC1-α suppresses a broad inﬂammatory response,
controls muscle plasticity, and mediates some of the beneﬁcial effects
of the exercise (Handschin and Spiegelman, 2008). However, recent ev-
idence showed that PGC-1-α expression in the skeletal muscle depends
on the exercise intensity, being evident only above the lactate threshold
(Tobina et al., 2011). These ﬁndings conﬁrm that the intensity of walk-
ing could be one of the major factors toward inﬂammation reduction.
It is important to underline that our results are strongly limited by
the heterogeneity in the study design. In addition, nutritional regimes
play a key role in the investigated context, and might have been a pos-
sible confounding factor. Furthermore, the different methods to assess
physical activity in free-living context make the comparison of results
difﬁcult: further studies using objective assessmentmethods ofwalking
activity are encouraged. Moreover, the role played by biological inter-
and intra-individual measurement variability (Navarro et al., 2012) in
markers of chronic low-grade inﬂammation should be investigated fur-
ther. Last but not least, further inﬂammatory markers that could have a
role in describing low-grade inﬂammation (e.g. IL-10, adiponectin, lep-
tin) were not analysed in this work but could be the object of further
investigations.
Conclusion
No consensus regarding the efﬁcacy of walking in the reduction of
low-grade systemic inﬂammation appeared from this review, even
though its role cannot be excluded. The duration and intensity of the
intervention inﬂuence the skeletal muscle adaptations that determine
the ﬁnal outcome. It is plausible to conclude that the reduction of
adiposity mediates the reduction of inﬂammation, whereas the anti-
inﬂammatory effect elicited by IL-6 cannot be conﬁrmed. The level of
glucose tolerance does not seem to inﬂuence the ﬁnal outcome. An ob-
jective assessment in wider population studies, analysing the role
played by different duration and intensity could facilitate the deﬁnition
of a dose–response relationship that could be useful in deﬁning amodel
of the inﬂammatory process (Castiglione et al., 2013).
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